Pharnext op Healthcare Conference 2016 van Jefferies
PARIJS–(BUSINESS WIRE)– Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), een Frans biofarmaceutisch bedrijf dat een geavanceerd medicijnportfolio tegen neurodegeneratieve ziekten ontwikkelt, heeft aangekondigd deel te nemen aan de Healthcare Conference 2016 van Jefferies in Londen. Dit evenement vindt van 16 tot 17 november plaats in het Waldorf Hotel in Londen.
De conferentie is de grootste Europese bijeenkomst voor de medische sector. Bedrijven uit de hele wereld bezoeken het evenement: Biotechnologischebedrijven, farmaceuten, poducenten van generieke geneesmiddelen en dienstverleners. Vorig jaar heette de conferentie van Jefferies meer dan driehonderd bedrijven en 1200 bezoekers welkom. De afgelopen editie kende bovendien 3700 vergaderingen van bedrijven en investeerders.
Pharnext to Attend Jefferies 2016 London Healthcare Conference |
|||||
|
PARIS–(BUSINESS WIRE)– Regulatory News: Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), a French biopharmaceuticals company developing an advanced portfolio of products in the field of neurodegenerative diseases, announces today its participation at the Jefferies 2016 London Healthcare Conference taking place November 16-17 at the Waldorf Hotel in London, UK. This Conference is the largest healthcare meeting in Europe dedicated to companies from around the world: biotechnologies, pharmaceuticals, generics, medtechs and healthcare services. Last year, the Jefferies conference hosted over 300 participating companies, 1,200 attendees and 3,700 B2B and investor meetings. ABOUT PHARNEXT Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPIE®. Pharnext identifies and develops synergetic combinations of drugs that are already being used for other diseases. These PLEOMEDICAMENT® are developed at new lower doses and repositioned into new indications. The PLEOMEDICAMENT® offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team. The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287). For more information, visit www.pharnext.com . View source version on businesswire.com:http://www.businesswire.com/news/home/20161103005151/en/ Contacts Pharnext |
|||||